At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Aromatase Inhibitor, Laboratory Biomarker Analysis, and 3 other interventions for Estrogen Receptor and/or Progesterone Receptor Positive and 2 related conditions. Completed, enrolled 2 participants across 9 sites.
Detailed Summary
This phase IIA trial studies the side effects of ribociclib and aromatase inhibitor and how well they work in treating participants with hormone receptor positive breast cancer that has spread to other places in the body. Ribociclib and aromatase inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Interventions
Aromatase inhibitor per treating investigator's discretion
Correlative studies
Correlative studies
Ancillary studies
Given PO